Table 5.

Results of univariate log rank analyses for the risk on local recurrence, the risk on distant metastases and the survival.

		local recurrence %				distant metastases %				cumulative survival %
		(2 year)				(2 year)				(2 year)
cell type		none/few	moderate	many	p-value	none/few	moderate	many	p-value	none/few	moderate	many	p-value
eosinophils
	intratumoral	18	26	34	0.45	30	54	56	0.08	72	67	62	0.94
	peritumoral	42	24	14	0.007*	62	48	35	0.009*	56	65	83	0.0008*
neutrophils
	intratumoral	35	23	23	0.42	46	49	47	0.85	61	68	73	0.66
	peritumoral	44	-	22	0.02*	52	-	48	0.88	48	-	72	0.19
mast cells
	intratumoral	42	23	20	0.17	65	47	39	0.08	45	74	71	0.006*
	peritumoral	44	18	15	0.007*	86	38	21	<0.0001*	43	78	73	<0.0001*
macrophages
	intratumoral	41	25	9	0.03*	63	50	28	0.03*	56	70	75	0.006*
	peritumoral	27	21	17	0.70	54	31	20	0.007*	70	68	67	0.50
NK cells
	intratumoral	36	-	20	0.03*	50	-	47	0.58	57	-	73	0.15
	peritumoral	27>	-	23	0.65	52	-	40	0.22	68	-	68	0.87
T cells (CD3)
	intratumoral	35	29	13	0.08	76	42	32	<0.0001*	57	67	75	0.002*
	peritumoral	25	23	25	0.67	63	41	47	0.02*	60	70	69	0.17
CD4 T cells
	intratumoral	33	31	10	0.01*	48	47	46	0.55	66	60	78	0.21
	peritumoral	36	28	14	0.10	54	53	46	0.90	66	65	70	0.51
CD8 T cells
	intratumoral	34	22	22	0.19	71	42	37	0.0005*	58	73	69	0.01*
	peritumoral	27	-	20	0.11	58	-	19	0.002*	60	-	86	0.05

The marked cell types (^*) show a significant correlation with prognosis. Median follow up is 35.4 months, n = 160